.
GBY financial statements
* Numbers in thousands
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
Capitalization * |
124 967 | 222 514 | 236 154 | 282 766 | 294 305 | 297 663 | 329 436 | 408 994 | 856 663 | 1 326 084 | 590 392 |
EV * |
108 201 | 200 835 | 225 968 | 276 736 | 224 823 | 275 602 | 279 610 | 268 576 | 779 449 | 1 198 445 | 1 198 445 |
Stock price € |
2.474 | 4.219 | 4.219 | 4.219 | 4.219 | 4.219 | 4.219 | 4.219 | 7.641 | 11.828 | 5.266 |
Number of shares * |
50 512 | 52 741 | 55 974 | 67 022 | 69 757 | 70 553 | 78 084 | 96 941 | 112 114 | 112 114 | 112 114 |
EPS |
-0,71 | -0,42 | -0,48 | -0,39 | -0,58 | -1,02 | -0,70 | -0,70 | -0,85 | -1,08 | -1,08 |
Revenue * |
10 319 | 21 655 | 24 133 | 45 870 | 39 539 | 19 389 | 36 567 | 84 452 | 102 428 | 118 192 | 118 192 |
Net income * |
-35 750 | -22 264 | -26 624 | -26 417 | -40 703 | -71 658 | -54 568 | -68 334 | -95 186 | -120 996 | -120 996 |
Operating profit * |
-35 821 | -22 198 | -26 646 | -26 551 | -46 856 | -72 559 | -56 361 | -77 150 | -105 180 | -129 552 | -129 552 |
Total liabilities * |
7 204 | 17 637 | 19 128 | 36 579 | 24 796 | 21 696 | 98 841 | 223 138 | 204 777 | 441 184 | 441 184 |
Net debt * |
-16 766 | -21 679 | -10 186 | -6 030 | -69 482 | -18 116 | -25 088 | -112 729 | -36 022 | -89 243 | -89 243 |
Total assets * |
87 336 | 82 533 | 140 838 | 243 212 | 217 235 | 157 891 | 286 741 | 590 395 | 637 516 | 938 550 | 938 550 |
Equity * |
80 132 | 64 896 | 121 710 | 206 633 | 192 439 | 136 195 | 187 900 | 366 518 | 432 554 | 498 234 | 498 234 |
Cash and investments * |
84 132 | 63 547 | 92 813 | 178 962 | 209 000 | 142 535 | 243 308 | 400 133 | 362 474 | 641 423 | 641 423 |
Over the past 10 years, the maximum capitalization of Sangamo Therapeutics, Inc. is 1 326 084, the minimum is 124 967. Maximum net income 0, Minimum net income -120 996. The maximum price of GBY shares is 11.828, the minimum price is 2.474.
.
GBY valuation
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-3,50 | -9,99 | -8,87 | -10,70 | -7,23 | -4,15 | -6,04 | -5,99 | -9,00 | -10,96 | -4,88 |
P/B |
1,56 | 3,43 | 1,94 | 1,37 | 1,53 | 2,19 | 1,75 | 1,12 | 1,98 | 2,66 | 1,18 |
P/S |
12,11 | 10,28 | 9,79 | 6,16 | 7,44 | 15,35 | 9,01 | 4,84 | 8,36 | 11,22 | 5,00 |
E/P |
-29% | -10% | -11% | -9% | -14% | -24% | -17% | -17% | -11% | -9% | -20% |
P/FCF |
-4,72 | -25,27 | -11,86 | -44,91 | -8,15 | -4,47 | 44,35 | -69,17 | -5,19 | 8,55 | 3,81 |
.
GBY profitability
Year |
2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
ROE |
-45% | -34% | -22% | -13% | -21% | -53% | -29% | -19% | -22% | -24% | |
ROA |
-41% | -27% | -19% | -11% | -19% | -46% | -19% | -14% | -17% | -14% | |
ROIC |
-45% | -30% | -20% | -12% | -24% | -50% | -23% | -15% | -19% | -16% |